9.95
0.94 (10.43%)
Penutupan Terdahulu | 9.01 |
Buka | 9.14 |
Jumlah Dagangan | 122,513 |
Purata Dagangan (3B) | 57,842 |
Modal Pasaran | 436,717,440 |
Harga / Pendapatan (P/E TTM) | 199.00 |
Harga / Jualan (P/S) | 48.31 |
Harga / Buku (P/B) | 23.00 |
Julat 52 Minggu | |
Tarikh Pendapatan | 28 Apr 2025 |
Margin Keuntungan | 28.99% |
Margin Operasi (TTM) | -68.64% |
EPS Cair (TTM) | 0.050 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -36.10% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 136.50% |
Nisbah Semasa (MRQ) | 10.71 |
Aliran Tunai Operasi (OCF TTM) | 2.08 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.27 M |
Pulangan Atas Aset (ROA TTM) | 7.18% |
Pulangan Atas Ekuiti (ROE TTM) | 14.83% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Instruments & Supplies (US) | Menurun | Bercampur |
Medical Instruments & Supplies (Global) | Menurun | Menurun | |
Stok | Anbio Biotechnology | - | - |
AISkor Stockmoo
Konsensus Penganalisis | -2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -3.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 2.0 |
Purata | -0.75 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |
|
Sektor | Healthcare |
Industri | Medical Instruments & Supplies |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 4.78% |
% Dimiliki oleh Institusi | 4.94% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
15 May 2025 | Pengumuman | Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |